{"id":"ramucirumab-imc-1121b","safety":{"commonSideEffects":[{"rate":"20-30%","effect":"Fatigue"},{"rate":"10-20%","effect":"Headache"},{"rate":"10-20%","effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL1743062","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By binding to VEGFR2, ramucirumab prevents the formation of new blood vessels, which is essential for tumor growth and metastasis. This mechanism is particularly effective in treating cancers that are highly vascularized.","oneSentence":"Ramucirumab is a monoclonal antibody that targets the vascular endothelial growth factor receptor 2 (VEGFR2), inhibiting angiogenesis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:52:09.976Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic gastric cancer"},{"name":"Non-small cell lung cancer"},{"name":"Advanced or metastatic breast cancer"}]},"trialDetails":[{"nctId":"NCT06203600","phase":"PHASE2, PHASE3","title":"Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-06-24","conditions":"Advanced Esophageal Adenocarcinoma, Advanced Gastric Adenocarcinoma, Advanced Gastroesophageal Junction Adenocarcinoma","enrollment":224},{"nctId":"NCT04310007","phase":"PHASE2","title":"Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-07-13","conditions":"Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8","enrollment":117},{"nctId":"NCT03008278","phase":"PHASE1, PHASE2","title":"Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2018-02-06","conditions":"Metastatic Esophageal Carcinoma, Metastatic Gastric Carcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma","enrollment":51},{"nctId":"NCT04340882","phase":"PHASE2","title":"Phase 2 DoceRamPem for Patients With Metastatic or Recurrent NSCLC Who Progressed on Platinum-Doublet and PD-1/PD-L1 Blockade","status":"ACTIVE_NOT_RECRUITING","sponsor":"Emory University","startDate":"2020-06-05","conditions":"Metastatic Non-Small Lung Cell Cancer, Recurrent Non-Small Lung Cell Cancer, Stage IV Lung Cancer AJCC v8","enrollment":30},{"nctId":"NCT06616584","phase":"PHASE2, PHASE3","title":"Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)","status":"RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2025-05-22","conditions":"Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8","enrollment":378},{"nctId":"NCT06031688","phase":"PHASE2","title":"Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)","status":"RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2024-08-08","conditions":"Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8","enrollment":56},{"nctId":"NCT05642572","phase":"PHASE2","title":"Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)","status":"RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2023-05-05","conditions":"Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8","enrollment":66},{"nctId":"NCT06675136","phase":"PHASE1","title":"Nab-Paclitaxel PIPAC in Combination With Paclitaxel and Ramucirumab for the Treatment of Stomach Cancer With Peritoneal Metastases","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2025-10-29","conditions":"Clinical Stage IVB Gastric Cancer AJCC v8, Metastatic Gastric Adenocarcinoma, Metastatic Malignant Neoplasm in the Peritoneum","enrollment":30},{"nctId":"NCT04205968","phase":"PHASE2","title":"Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers","status":"RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2020-06-01","conditions":"Metastatic Small Intestinal Adenocarcinoma, Stage III Small Intestinal Adenocarcinoma AJCC v8, Stage IIIA Small Intestinal Adenocarcinoma AJCC v8","enrollment":94},{"nctId":"NCT03694002","phase":"PHASE2","title":"Carboplatin and Paclitaxel With or Without Ramucirumab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Thymic Cancer That Cannot Be Removed by Surgery","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"2019-03-20","conditions":"Locally Advanced Thymic Carcinoma, Metastatic Thymic Carcinoma, Recurrent Thymic Carcinoma","enrollment":21},{"nctId":"NCT02597036","phase":"PHASE1","title":"A Study of LY3127804 With Ramucirumab in Participants With Advanced Solid Tumors","status":"TERMINATED","sponsor":"Eli Lilly and Company","startDate":"2015-11-06","conditions":"Solid Tumors","enrollment":62},{"nctId":"NCT04120454","phase":"PHASE2","title":"Ramucirumab and Pembrolizumab for the Treatment of EGFR Mutant Recurrent or Metastatic Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"Ohio State University Comprehensive Cancer Center","startDate":"2020-06-17","conditions":"Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8","enrollment":6},{"nctId":"NCT05633602","phase":"PHASE3","title":"Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2023-03-14","conditions":"Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8","enrollment":838},{"nctId":"NCT05096663","phase":"PHASE2, PHASE3","title":"Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)","status":"ACTIVE_NOT_RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2022-03-15","conditions":"Advanced Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8","enrollment":82},{"nctId":"NCT02307812","phase":"","title":"Ramucirumab Use in Combination With Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma; Temporary Authorization for Use (ATU) in France","status":"APPROVED_FOR_MARKETING","sponsor":"Eli Lilly and Company","startDate":"","conditions":"Gastric Cancer, Gastroesophageal Junction Adenocarcinoma","enrollment":""},{"nctId":"NCT02065765","phase":"","title":"International Expanded Access Program to Provide Ramucirumab for the Treatment of Metastatic Gastric Cancer","status":"APPROVED_FOR_MARKETING","sponsor":"Eli Lilly and Company","startDate":"","conditions":"Metastatic Gastric Cancer, Metastatic Adenocarcinoma of the Gastroesophageal Junction","enrollment":""},{"nctId":"NCT03971474","phase":"PHASE2","title":"Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial)","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"2019-05-28","conditions":"Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8","enrollment":166},{"nctId":"NCT02443324","phase":"PHASE1","title":"A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2015-07-29","conditions":"Gastric Adenocarcinoma, Adenocarcinoma of the Gastroesophageal Junction, Non-small Cell Lung Cancer","enrollment":175},{"nctId":"NCT04660760","phase":"PHASE2","title":"Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer","status":"RECRUITING","sponsor":"Academic and Community Cancer Research United","startDate":"2021-06-16","conditions":"Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8","enrollment":116},{"nctId":"NCT05045404","phase":"PHASE2","title":"Poziotinib and Ramucirumab for the Treatment of EGFR Exon 20 Mutant Stage IV Non-small Cell Lung Cancer","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-06-16","conditions":"Metastatic Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8","enrollment":""},{"nctId":"NCT01079780","phase":"PHASE2","title":"Irinotecan Hydrochloride and Cetuximab With or Without Ramucirumab in Treating Patients With Advanced Colorectal Cancer With Progressive Disease After Treatment With Bevacizumab-Containing Chemotherapy","status":"COMPLETED","sponsor":"Eastern Cooperative Oncology Group","startDate":"2011-01-18","conditions":"Colorectal Cancer","enrollment":136},{"nctId":"NCT02520141","phase":"PHASE2","title":"Ramucirumab in Treating Patients With Advanced or Metastatic, Previously Treated Biliary Cancers That Cannot Be Removed by Surgery","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-12-29","conditions":"Cholangiocarcinoma, Liver and Intrahepatic Bile Duct Carcinoma, Stage III Gallbladder Cancer AJCC v7","enrollment":61},{"nctId":"NCT04675983","phase":"PHASE3","title":"A Study of Sintilimab Plus Ramucirumab as First-line Treatment for G/EGJ Adenocarcinoma (ORIENT-106)","status":"TERMINATED","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2021-03-10","conditions":"Gastric Adenocarcinoma","enrollment":36},{"nctId":"NCT02317991","phase":"PHASE2","title":"Study of Nab-Paclitaxel and Ramucirumab as Second-line Treatment for Patients With Metastatic Gastroesophageal Cancer","status":"COMPLETED","sponsor":"SCRI Development Innovations, LLC","startDate":"2015-05-05","conditions":"Gastroesophageal Cancer","enrollment":65},{"nctId":"NCT02898077","phase":"PHASE3","title":"A Study of Paclitaxel With or Without Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Cancer","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2017-03-02","conditions":"Gastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma","enrollment":440},{"nctId":"NCT02539225","phase":"PHASE2","title":"A Study of Ramucirumab in Participants With Gastric or Gastroesophageal Junction Adenocarcinoma","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2015-10-05","conditions":"Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma","enrollment":191},{"nctId":"NCT01515306","phase":"PHASE2","title":"A Study of Ramucirumab (IMC-1121B) and Paclitaxel in Participants With Solid Tumors","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2012-07-19","conditions":"Malignant Solid Tumor","enrollment":48},{"nctId":"NCT00703326","phase":"PHASE3","title":"Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2008-08-06","conditions":"Breast Cancer","enrollment":1144},{"nctId":"NCT02314117","phase":"PHASE3","title":"A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach Cancer","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2015-01-20","conditions":"Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma","enrollment":645},{"nctId":"NCT02564198","phase":"PHASE1","title":"A Study of Ramucirumab (LY3009806) in Children With Refractory Solid Tumors","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2015-12-11","conditions":"Pediatric Solid Tumor, Refractory Tumor, Recurrent Tumor","enrollment":29},{"nctId":"NCT02082210","phase":"PHASE1, PHASE2","title":"A Study of Emibetuzumab in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2014-03-07","conditions":"Advanced Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma","enrollment":97},{"nctId":"NCT04267913","phase":"PHASE2","title":"Testing of TAK228 (MLN0128, Sapanisertib) Plus Docetaxel to the Usual Standard of Care for Advanced Squamous Cell Lung Cancer (A Lung-MAP Treatment Trial)","status":"WITHDRAWN","sponsor":"SWOG Cancer Research Network","startDate":"2020-09-05","conditions":"Lung Squamous Cell Carcinoma, Recurrent Lung Carcinoma, Stage IV Lung Cancer AJCC v8","enrollment":""},{"nctId":"NCT02443883","phase":"PHASE2","title":"A Phase 2 Study of Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Junction (GEJ) Cancer","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2015-07-07","conditions":"Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma","enrollment":164},{"nctId":"NCT02514551","phase":"PHASE2","title":"A Study of Ramucirumab (LY3009806) in Combination With Paclitaxel in Participants With Gastric Cancer","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2015-10-12","conditions":"Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma","enrollment":245},{"nctId":"NCT03739801","phase":"PHASE1, PHASE2","title":"MM-398 and Ramucirumab in Treating Patients With Gastric Cancer or Gastroesophageal Junction Adenocarcinoma","status":"WITHDRAWN","sponsor":"University of Southern California","startDate":"2020-04-06","conditions":"Locally Advanced Unresectable Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Metastatic Unresectable Gastric Adenocarcinoma","enrollment":""},{"nctId":"NCT01983878","phase":"PHASE2","title":"A Study of Ramucirumab in Treating Japanese Participants With Metastatic Gastric or Gastroesophageal Junction Cancer","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2013-12","conditions":"Gastric Cancer","enrollment":36},{"nctId":"NCT01703091","phase":"PHASE2","title":"A Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2012-12","conditions":"Non-small Cell Lung Cancer Metastatic","enrollment":197},{"nctId":"NCT00721162","phase":"PHASE2","title":"Study of Ramucirumab in Ovarian Cancer","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2008-08","conditions":"Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma","enrollment":60},{"nctId":"NCT01183780","phase":"PHASE3","title":"A Study in Second Line Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2010-12-02","conditions":"Colorectal Cancer","enrollment":1072},{"nctId":"NCT00917384","phase":"PHASE3","title":"Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcinoma","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2009-08","conditions":"Gastric Cancer, Adenocarcinoma","enrollment":355},{"nctId":"NCT01168973","phase":"PHASE3","title":"A Study of Chemotherapy and Ramucirumab Versus Chemotherapy Alone in Second Line Non-Small Cell Lung Cancer (NSCLC) Participants Who Received Prior First Line Platinum-based Chemotherapy","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2010-12","conditions":"Non-Small Cell Lung Cancer","enrollment":1253},{"nctId":"NCT01170663","phase":"PHASE3","title":"A Study of Paclitaxel With or Without Ramucirumab (IMC-1211B) in Metastatic Gastric Adenocarcinoma","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2010-12","conditions":"Gastric Cancer","enrollment":665},{"nctId":"NCT01160744","phase":"PHASE2","title":"A Study of Pemetrexed and Carboplatin/Cisplatin or Gemcitabine and Carboplatin/Cisplatin With or Without IMC-1121B in Participants Previously Untreated With Recurrent or Advanced Non-Small Cell Lung Cancer (NSCLC)","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2010-09","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":280},{"nctId":"NCT01282463","phase":"PHASE2","title":"Study of Ramucirumab or Icrucumab (IMC-18F1) With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2011-04","conditions":"Carcinoma of Urinary Tract, Urethral Carcinoma, Carcinoma of Ureter","enrollment":148},{"nctId":"NCT01234402","phase":"PHASE2","title":"Study of Icrucumab (IMC-18F1) or Ramucirumab Drug Product (DP) in Combination With Capecitabine or Capecitabine on Previously Treated Breast Cancer Patients","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2011-03","conditions":"Breast Cancer","enrollment":153},{"nctId":"NCT01111604","phase":"PHASE2","title":"A Study of Ramucirumab or Icrucumab in Colorectal Cancer","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2010-08","conditions":"Colon Cancer, Rectal Cancer","enrollment":158},{"nctId":"NCT01634555","phase":"PHASE2","title":"A Study to Assess the Pharmacokinetics of Ramucirumab (IMC-1121B) in Combination With FOLFIRI","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2012-10","conditions":"Solid Tumors","enrollment":29},{"nctId":"NCT02069041","phase":"PHASE1","title":"A Study of Ramucirumab (LY3009806) in Participants With Advanced Liver Cancer","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2014-04","conditions":"Carcinoma, Hepatocellular","enrollment":8},{"nctId":"NCT01285037","phase":"PHASE1","title":"A Study of LY2801653 in Advanced Cancer","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2009-09-09","conditions":"Cancer","enrollment":190},{"nctId":"NCT02359058","phase":"PHASE1","title":"A Study of Ramucirumab Combination Therapy in Japanese Participants Who Have Advanced Stomach Cancer","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2015-02","conditions":"Stomach Neoplasms","enrollment":18},{"nctId":"NCT00895180","phase":"PHASE2","title":"Ramucirumab or Anti-PDGFR Alpha Monoclonal Antibody IMC-3G3 in Treating Patients With Recurrent Glioblastoma Multiforme","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2010-07","conditions":"Adult Glioblastoma Multiforme","enrollment":80},{"nctId":"NCT01427933","phase":"PHASE2","title":"A Study of Ramucirumab (IMC-1121B) in Combination With Eribulin Versus Eribulin Alone in Participants With Breast Cancer","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2011-11","conditions":"Breast Cancer","enrollment":141},{"nctId":"NCT01682135","phase":"PHASE1","title":"A Study in Participants With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2012-11","conditions":"Solid Tumor","enrollment":28},{"nctId":"NCT01140347","phase":"PHASE3","title":"A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2010-10","conditions":"Hepatocellular Carcinoma","enrollment":565},{"nctId":"NCT01017731","phase":"PHASE2","title":"Study of Ramucirumab (IMC-1121B) Therapy and Corrected QT (QTc) Interval Changes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2009-11","conditions":"Cancer, Solid Tumor","enrollment":68},{"nctId":"NCT00735696","phase":"PHASE2","title":"A Study of Ramucirumab (IMC-1121B) With Paclitaxel and Carboplatin in Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2009-01","conditions":"Non Small Cell Lung Cancer","enrollment":41},{"nctId":"NCT00683475","phase":"PHASE2","title":"A Study of IMC-A12 or Ramucirumab Plus Mitoxantrone and Prednisone in Prostate Cancer","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2008-08","conditions":"Prostate Cancer","enrollment":138},{"nctId":"NCT01567163","phase":"PHASE2","title":"A Study of Ramucirumab and Docetaxel in Participants With Solid Tumors","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2012-07","conditions":"Malignant Solid Tumor","enrollment":22},{"nctId":"NCT01246960","phase":"PHASE2","title":"A Study of Ramucirumab in Participants With Gastric, Esophageal, and Gastroesophageal Cancer","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2011-04","conditions":"Stomach Cancer, Esophageal Cancer","enrollment":168},{"nctId":"NCT00627042","phase":"PHASE2","title":"Study of IMC-1121B (Ramucirumab) in Participants With Liver Cancer Who Have Not Previously Been Treated With Chemotherapy","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2008-02","conditions":"Hepatocellular Carcinoma","enrollment":42},{"nctId":"NCT01286818","phase":"PHASE1","title":"A Study of Irinotecan, Levofolinate, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab (IMC-1121B)","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2011-02","conditions":"Colorectal Carcinoma","enrollment":6},{"nctId":"NCT00533702","phase":"PHASE2","title":"A Study of IMC-1121B (Ramucirumab) With or Without Dacarbazine in Metastatic Malignant Melanoma","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2007-11","conditions":"Metastatic Malignant Melanoma","enrollment":106},{"nctId":"NCT00515697","phase":"PHASE2","title":"A Study of Ramucirumab in Participants With Metastatic Renal Cell Carcinoma","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2007-11","conditions":"Metastatic Renal Cell Carcinoma","enrollment":39},{"nctId":"NCT01253525","phase":"PHASE1","title":"Study of Weekly Paclitaxel With Ramucirumab in Participants With Advanced Gastric Adenocarcinomas","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2010-11","conditions":"Adenocarcinoma","enrollment":6},{"nctId":"NCT01005355","phase":"PHASE1","title":"Study of IMC-1121B in Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2009-09","conditions":"Advanced Solid Tumors","enrollment":15},{"nctId":"NCT01256567","phase":"PHASE1","title":"A Study of Ramucirumab (IMC-1121B) in Participants With Breast Cancer","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2010-12","conditions":"Breast Cancer, Metastatic Breast Cancer","enrollment":7},{"nctId":"NCT00862784","phase":"PHASE2","title":"A Study of IMC-1121B (Ramucirumab) in Colorectal Cancer","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2009-04","conditions":"Colorectal Carcinoma","enrollment":48},{"nctId":"NCT00786383","phase":"PHASE1","title":"Study of IMC-1121B in Patients With Advanced Solid Tumors Not Responding To Standard Therapy","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2006-02","conditions":"Cancer","enrollment":25},{"nctId":"NCT00793975","phase":"PHASE1","title":"Study of IMC-1121B in Patients With Tumors That Have Not Responded to Therapy","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2005-01","conditions":"Advanced Solid Tumors","enrollment":37}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":21,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["IMC-1121B","LY3009806","Ramucirumab"],"phase":"phase_3","status":"active","brandName":"ramucirumab (IMC-1121B)","genericName":"ramucirumab (IMC-1121B)","companyName":"Eli Lilly and Company","companyId":"eli-lilly","modality":"Biologic","firstApprovalDate":"","aiSummary":"Ramucirumab is a medication used in clinical trials to treat various stages of gallbladder and intrahepatic cholangiocarcinoma cancers, including Stage III gallbladder cancer and Stage III intrahepatic cholangiocarcinoma. It is often used in combination with docetaxel and is being studied in conjunction with laboratory biomarker analysis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":4,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}